PGM’s multifaceted roles as both a glycolytic enzyme and PLMG binder make it a promising therapeutic target; future work on developing SmPGM-specific inhibitory drugs and SmPGM vaccines may advance solutions to treat and eliminate schistosomiasis. This evidence concerns the gene VCAN and schistosomiasis.